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Handling Executive Committee member: Prof. Marco Colonna 
 
Please note that the correspondence below does not include the standard editorial instructions regarding 
preparation and submission of revised manuscripts, only the scientific revisions requested and addressed.  
 
 
First Editorial Decision – 1 September 2014 
 
Dear Dr. Gursel,  
 
Manuscript ID eji.201445133 entitled "Enhancement of Immunostimulatory Activity of Cyclic Dinucleotides 
through Complexation with a Cell Penetrating Peptide or Combined Use with CpG ODN" which you 
submitted to the European Journal of Immunology has been reviewed. 
  
The comments of the referee are included at the bottom of this letter. A revised version of your manuscript 
that takes into account the comments of the referee will be reconsidered for publication. 
  
You should also pay close attention to the editorial comments included below. In particular, please edit 
your figure legends to follow Journal standards as outlined in the editorial comments. Failure to do this will 
result in delays in the re-review process. 
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Please note that submitting a revision of your manuscript does not guarantee eventual acceptance, and 
that your revision will be re-reviewed by the referee before a decision is rendered. 
  
If the revision of the paper is expected to take more than three months, please inform the editorial office. 
Revisions taking longer than six months may be assessed by new referee(s) to ensure the relevance and 
timeliness of the data. 
  
Once again, thank you for submitting your manuscript to European Journal of Immunology and we look 
forward to receiving your revision. 
  
Yours sincerely,  
Laura Soto Vazquez  
 
On behalf of Prof. Marco Colonna  
 
Editorial Office  
European Journal of Immunology  





Reviewer: 1  
 
Comments to the Author  
In this manuscript Yildiz and colleagues investigate the immunostimulatory activity of cyclic dinucleotides 
complexed with a cell penetrating peptide or in combination with CpG ODN. They show that use of a cell 
penetrating peptide enhances the cellular delivery and the biological activity of cylic-di-GMP and that 
activation of both TLR-dependent and independent DNA recognition pathways results in synergistic 
activity with respect to cytokine production, cell maturation and humoral/cellular immunity. I find the data 
presentation and the discussion of findings in this manuscript extremely weak. However, the fact that c-di-
GMP is a weak STING ligand in human but not mouse and that cGAMP is a strong STING ligand in both 
mouse and human is useful information for those involved in vaccine design. 
  
Figure 1B, a more appropriate gating strategy would be to gate on MHCII+ cells then measure %FAM-c-
di-GMP+ and %FAM-c-di-GMP– cells. Also, it looks like both MHCII hi and MHC lo cells take up FAM-c-di-
GMP. What are these populations? cDC, pDC, B cells? 
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Based on Figure 2C and supporting information (S1) it looks like transfection of c-di-GMP 15 uM is 
equivalent or superior to c-di-GMP/Arg 15 uM at inducing MHCII/CD86 expression as well as TNFa and 
IL-12 production. However, transfection of c-di-GMP resulted in IL-6 production while c-di-GMP/Arg did 
not. Although the authors argue that “complexation with Arg(9) peptide increases the cytosolic availability 
and the immunostimulatory activity of c-di-GMP and may replace the need to transfect the drug through 
the use of cytotoxic lipid-based transfection reagents” it does not appear to be more robust at inducing 
maturation or cytokine production compared to transfection. Furthermore the authors comment on 
cytotoxicity of transfection reagents but they do not provide data on the viability of cells after treatment 
with c-di-GMP/Arg. And, what are the levels of these cytokines in supernatants? If standards were used in 
these assays then the authors should provide concentrations rather than OD values. 
  
It would be helpful to show representative FACs plots for data shown in Figure 1C and to distinguish which 
populations of cells upregulate MHCII and CD86 after treatments. I also believe that a better way to 
express this data (and the data shown in Figure 2A) would be to show mean fluorescence intensities of 
MHCII and CD86. 
  
In Figure 2B the fact that IL12 is not further increased after adding c-di-GMP to CpG maybe suggests that 
the responding cells are already producing optimal levels of IL12 or they are not affected by the addition of 
c-di-GMP. Was any analyses done to determine which cell types were producing cytokines after 
treatments? And, why were IFN-I levels not measured here? 
  
Data shown in Figures 3 and S2 indicate that OVA + c-di-GMP or c-di-GMP/Arg induces IgG1 or a type 2 
response while CpG or the addition of CpG to c-di-GMP induces IgG2c or a type 1 response. And, why 
does OVA + c-di-GMP/Arg induce more IgG1 than OVA + c-di-GMP but similar levels of IgG2c? The 
authors should discuss the significance of these findings. 
  
In Figure 3B and 3C, tumor experiments were performed on OVA vaccinated mice. Interestingly, mice 
immunized with OVA + CpG had a very poor response compared to those immunized with OVA + c-di-
GMP or OVA + c-di-GMP/Arg. Moreover, addition of CpG to c-di-GMP was equivalent to c-di-GMP/Arg on 
its own. Therefore, these data suggest that any adjuvant affect of CpG or TLR9 activation is negligible in 
this model and that c-di-GMP or STING activation is strong enough to promote tumor rejection. This is not 
discussed but should be. I am also wondering why no experiments were performed to look at OVA specific 
T cells in these animals since rejection of EG7 is largely dependent on CTLs. 
  
Figure 4A. Showing bead/analyte intensities in FACs plot form is NOT a common or suitable way to 
express CBA data. The authors need to graphically illustrate cytokine levels (i.e. bar graph) because the 
data shown tells me nothing. 
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 Data in Figure 4B and S3 suggests that adding CpG to c-di-GMP actually suppresses IP-10 producing 
cells compared to CpG alone. And the authors do not comment on the fact that there is really no 
difference in the percentage of IP-10 producing cells with cGAMP vs CpG + cGAMP even though the MFI 
of IP-10 producing cells is increased with CpG + cGAMP relative to cGAMP alone. 
  
The authors conclude the results section by stating that 3’3’-cGAMP is more effective as an 
immunostimulatory agent for human use than c-di-GMP, which is important information however, the 
authors did not use cGAMP in vaccination or tumor experiments to show its effectiveness as an adjuvant. 
This could be addressed given that mouse cells appear to respond well to cGAMP. 
  
Spelling errors:  
Page 6 should be ‘assessment’  
Page 9 should be ‘augment the’  
Figure 4C should be ‘splenocytes’ 
 
 
First revision – authors’ response – 19 October 2014 
  
Point-by-point response to reviewer’s comments:  
In this manuscript Yildiz and colleagues investigate the immunostimulatory activity of cyclic dinucleotides 
complexed with a cell penetrating peptide or in combination with CpG ODN. They show that use of a cell 
penetrating peptide enhances the cellular delivery and the biological activity of cylic-di-GMP and that 
activation of both TLR-dependent and independent DNA recognition pathways results in synergistic 
activity with respect to cytokine production, cell maturation and humoral/cellular immunity. I find the data 
presentation and the discussion of findings in this manuscript extremely weak. However, the fact that c-di-
GMP is a weak STING ligand in human but not mouse and that cGAMP is a strong STING ligand in both 
mouse and human is useful information for those involved in vaccine design. 
 We thank the Reviewer for his valuable comments. We have modified data presentation as 
recommended by the reviewer (please see below) and expanded data discussion where indicated by the 
reviewer. 
 2-Figure 1B, a more appropriate gating strategy would be to gate on MHCII+ cells then measure %FAM-
c-di-GMP+ and %FAM-c-di-GMP- cells. Also, it looks like both MHCII hi and MHC lo cells take up FAM-c-
di-GMP. What are these populations? cDC, pDC, B cells? 
 We have now modified Fig. 1B as recommended. Furthermore, we have analyzed the cell populations 
that internalized FAM-labeled c-di-GMP. This new data is presented in the new Supporting information 
Fig. 1 and accompanying text is included in the revised manuscript. 
 3- Based on Figure 2C and supporting information (S1) it looks like transfection of c-di-GMP 15 uM is 
equivalent or superior to c-di-GMP/Arg 15 uM at inducing MHCII/CD86 expression as well as TNFa and 
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IL-12 production. However, transfection of c-di-GMP resulted in IL-6 production while c-di-GMP/Arg did 
not. Although the authors argue that â€œcomplexation with Arg(9) peptide increases the cytosolic 
availability and the immunostimulatory activity of c-di-GMP and may replace the need to transfect the drug 
through the use of cytotoxic lipid-based transfection reagentsâ€• it does not appear to be more robust at 
inducing maturation or cytokine production compared to transfection. Furthermore the authors comment 
on cytotoxicity of transfection reagents but they do not provide data on the viability of cells after treatment 
with c-di-GMP/Arg. And, what are the levels of these cytokines in supernatants? If standards were used in 
these assays then the authors should provide concentrations rather than OD values. 
 As stated in the original text of the manuscript we never claimed that complexation was more robust at 
inducing maturation or cytokine production than transfection. The sentence we used was “The 
immunostimulatory activity of c-di-GMP/Arg(9) was comparable to Lipofectamine 2000 transfected groups, 
suggesting that the active drug was efficiently transferred to the cytosol”. 
 Related with the IL-6 data, we had noted in the original manuscript that “neither the free ligand nor its 
Arg(9) complexes induced detectable IL-6 secretion”. Transfected c-di-GMP indeed induces this cytokine. 
We believe that this is an off-target effect of the cationic lipid based transfection reagent. Please find for 
the Reviewer`s attention, the below data showing that transfection reagents from various manufacturers 
(X-tremeGENE, Transpass and Lipofectamine2000) all trigger IL- -1 
monocytes whereas the nonaarginine peptide does not (all reagents were used at their optimal 
concentrations as recommended by the manufacturer or at the concentrations we used in our stimulation 
experiments). 
  
Since IL- -6 (please see the reference by 
Mori T. et al, Int Immunol. 2011 Nov;23(11):701-12. doi: 10.1093/intimm/dxr077), we believe that the 
observed IL-6 secretion in transfected samples is the result of c-di-GMP-
transfection-reagent dependent IL-  
 Although Lipoplexes are very effective in vitro, they form aggregates in serum containing media, and 
cause complement activation and platelet aggregation in vivo, compromising their activity for in vivo 
applications (Liposome Technology: Entrapment of Drugs and Other Materials into Liposomes Volume II, 
3rd edition p. 274, Ed. Gregory Gregoriadis). Furthermore, toxicity associated with lipoplexes is a major 
concern for their in vivo use (Non-viral Vectors for Gene Therapy, Part 1 p.5 edited by Leaf Huang, Mien-
chie Hung, Ernst Wagner). In contrast, Arginine(9) at the concentrations used in our study has no such 
toxicity (G. Tunnemann et al, Journal of Peptide Science, vol. 14, no. 4, pp. 469–476, 2008). 
 Per the Reviewer’s request and to confirm that Arg(9)/c-di-GMP is not cytotoxic, we treated spleen cells 
with the complexes and then quantitated LDH release. This data is provided in Supporting information 
Figure 4 of the revised manuscript. 
 Finally, for the cytokine data provided in the supporting information figure 3, we have converted the raw 
OD values to concentrations (ng/ml) as requested by the Reviewer. 
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 It would be helpful to show representative FACs plots for data shown in Figure 1C and to distinguish 
which populations of cells upregulate MHCII and CD86 after treatments. I also believe that a better way to 
express this data (and the data shown in Figure 2A) would be to show mean fluorescence intensities of 
MHCII and CD86. 
 We have included the representative flow cytometric dot plots in the revised version in Supporting 
information Figure 2A. MFIs for various doses of transfected or Arg(9) complexed CDNs are presented in 
Supporting information Figure 2B. We also analyzed the cell populations that upregulated MHC Class II 
and CD86 (in CD11b+ macrophages, CD11c+ DCs and B220+ B cells). The cell population in which these 
markers were upregulated the most were the B220+ cells and the MFIs of MHCII and CD86 in this 
population (for unstimulated versus Arg(9)/c-di-GMP stimulated samples) are presented in Supporting 
information Figure 2C. 
 In Figure 2B the fact that IL12 is not further increased after adding c-di-GMP to CpG maybe suggests that 
the responding cells are already producing optimal levels of IL12 or they are not affected by the addition of 
c-di-GMP. Was any analyses done to determine which cell types were producing cytokines after 
treatments? And, why were IFN-I levels not measured here? 
 We have now included new -12 production 
from MHC Class II/CD11c double positive DCs in response to CDN, CpG or both. This data supports our 
 to IL-12 production. 
Based on published literature showing that CpG-ODN induced IL-12 production was independent of 
MAPK, PI3K, and IRF signaling pathways [Reference 22 in the revised manuscript] we think that the 
STING-dependent TBK1-IRF3 activation would be ineffective in augmenting the magnitude of CpG ODN-
induced IL-12 production and we have included this discussion in the main text (p.9). 
 The Type I interferon responses were indeed measured and part of that data was presented in Fig 4C 
(mouse splenoc
manuscript. Therefore we would like to bring this point to the Reviewer’s attention. 
 Data shown in Figures 3 and S2 indicate that OVA + c-di-GMP or c-di-GMP/Arg induces IgG1 or a type 2 
response while CpG or the addition of CpG to c-di-GMP induces IgG2c or a type 1 response. And, why 
does OVA + c-di-GMP/Arg induce more IgG1 than OVA + c-di-GMP but similar levels of IgG2c? The 
authors should discuss the significance of these findings. 
 We have clarified these findings by emphasizing that “complexation only augmented Th2-dependent IgG1 
responses but had no effect in Th-1 dependent IgG2c production” (p.10). 
 In Figure 3B and 3C, tumor experiments were performed on OVA vaccinated mice. Interestingly, mice 
immunized with OVA + CpG had a very poor response compared to those immunized with OVA + c-di-
GMP or OVA + c-di-GMP/Arg. Moreover, addition of CpG to c-di-GMP was equivalent to c-di-GMP/Arg on 
its own. Therefore, these data suggest that any adjuvant affect of CpG or TLR9 activation is negligible in 
this model and that c-di-GMP or STING activation is strong enough to promote tumor rejection. This is not 
discussed but should be. I am also wondering why no experiments were performed to look at OVA specific 
T cells in these animals since rejection of EG7 is largely dependent on CTLs. 
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 We would like emphasize the dose of CpG ODN used in our study (i.e. 10 µg/mouse) which is 5-X lower 
than the usual dose of 50 µg/mouse administered in similar tumor protection studies (for example please 
see, D. Karan et al, Int. J. Cancer: 121, 1520–1528 (2007)). Had we used a high dose of CpG ODN, we 
might not have seen synergism between CpG ODN and c-di-GMP. We clarified this issue in the revised 
manuscript (p.10). 
 We also respectfully disagree with the Reviewer’s interpretation of our data (“these data suggest that any 
adjuvant effect of CpG or TLR9 activation is negligible in this model and that c-di-GMP or STING 
activation is strong enough to promote tumor rejection”). Had this been true, the CpG+c-di-GMP group 
would have yielded identical results when compared to the c-di-GMP adjuvanted group. However, this is 
not the case and the combined group promoted significantly higher reduction in tumor growth when 
compared to the c-di-GMP adjuvanted group (Fig.3C, P<0.05). Evidence shows that liposomal CpG ODN 
formulations are much more effective than free CpG ODN in generating OVA-specific cytotoxic T cells and 
hence anti-tumor immunity (please see references by Y.Suzuki et al., Cancer Res 2004;64:8754-8760 and 
by D. Wakita et al., 2006, Int. Immunol.18(3):425-434.) Similarly, c-di-GMP/Arg represents a formulation 
strategy that might modify the immunostimulatory activity of the CDN in vivo. Therefore, we have limited 
the comparison of the CDN/CpG combined group to those obtained with the single use free ligands (i.e c-
di-GMP alone or the CpG ODN alone groups). Based on this comparison, size of tumors in the CDN/CpG 
group was significantly smaller when compared to single ligand adjuvants (P<0.05, Fig. 3C). 
 Finally, we had originall -vivo re-stimulation of 
spleen cells (with the SIINFEKL peptide) harvested from immunized mice. We thought that the results 
supported the data in Figure 3C but revealed no additional findings and thus elected not to present it. 
However, per the Reviewer’s request, we now show this data in Supporting information Fig. 7. 
 Figure 4A. Showing bead/analyte intensities in FACs plot form is NOT a common or suitable way to 
express CBA data. The authors need to graphically illustrate cytokine levels (i.e. bar graph) because the 
data shown tells me nothing. 
 We have modified Figure 4A as recommended by the Reviewer.  
Data in Figure 4B and S3 suggests that adding CpG to c-di-GMP actually suppresses IP-10 producing 
cells compared to CpG alone. And the authors do not comment on the fact that there is really no 
difference in the percentage of IP-10 producing cells with cGAMP vs CpG + cGAMP even though the MFI 
of IP-10 producing cells is increased with CpG + cGAMP relative to cGAMP alone. 
 We agree with the Reviewer and have modified the main text to clarify that c-di-GMP addition to CpG 
actually suppressed the IP-10 producing cells compared to CpG alone. However, for cGAMP vs 
CpG+cGAMP, although the % of IP-10 producing cells increased from 11.2 to 13.7, a number that 
appears to be too insignificant when all the cell populations are considered, when only the main IP-10 
producing population is analyzed (i.e. the CD14+ monocytes) this represents an increase from 60% to 
77% of the monocyte population, a 17% increase. Therefore, we consider this as an improvement and 
respectfully disagree with the Reviewer in his/her interpretation of “no difference in the percentage of IP-
10 producing cells”. 
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 The authors conclude the results section by stating that 3â€™3â€™-cGAMP is more effective as an 
immunostimulatory agent for human use than c-di-GMP, which is important information however, the 
authors did not use cGAMP in vaccination or tumor experiments to show its effectiveness as an adjuvant. 
This could be addressed given that mouse cells appear to respond well to cGAMP. 
 We thank the Reviewer for bringing this to our attention. We have modified the last part of the Results 
section to accomodate these comments. 
 Spelling errors:  
Page 6 should be â€˜assessmentâ€™  
Page 9 should be â€˜augment theâ€™  
Figure 4C should be â€˜splenocytesâ€™  
We thank the Reviewer for his thorough reading and identifying the spelling errors we have overlooked. 
These have been corrected in the revised manuscript. 
 
 
 Second Editorial Decision – 5 December 2014  
 
Dear Dr. Gursel,  
 
My apologies for the prolonged delay in processing the re-review of your revised manuscript ID 
eji.201445133.R1 entitled "Enhancement of Immunostimulatory Activity of Cyclic Dinucleotides through 
Complexation with a Cell Penetrating Peptide or Combined Use with CpG ODN" which you had submitted 
to the European Journal of Immunology. There was a delay in the referee re-evaluating your revision; 
furthermore we wanted to send the decisions for this and a companion submission, 201445132, together. 
The referee's opinion has been received and the comments of the referee are included at the bottom of 
this letter. 
  
Although the referee has recommended publication, some revisions to your manuscript have been 
requested. Therefore, I invite you to respond to the comments of the referee and revise your manuscript 
accordingly. 
  
You should also pay close attention to the editorial comments included below. *In particular, please edit 
your figure legends to follow Journal standards as outlined in the editorial comments. Failure to do this will 
result in delays in the re-review process.* 
  
If the revision of the paper is expected to take more than three months, please inform the editorial office. 
Revisions taking longer than six months may be assessed by new referees to ensure the relevance and 
timeliness of the data. 
  
Peer review correspondence 
Once again, thank you for submitting your manuscript to European Journal of Immunology. We look 
forward to receiving your revision. 
  
Yours sincerely,  
Karen Chu  
 
on behalf of Prof. Marco Colonna  
 
Dr. Karen Chu  
Editorial Office  
European Journal of Immunology  





Reviewer: 1  
 
Comments to the Author  
The manuscript has been improved however there are a few minor things that  
should be corrected prior to publication. Supporting Information Figure 1 and 2  
legend and text; I think it would be best to just state B220+ cells, CD11b+ cells 
 and CD11c+ cells rather than calling them B cells, macrophages or DC because  
the gating strategies here are very simplified. For example, gating on B220+  
cells may include B cells, plasmacytoid DC and NK cells while CD11b+ cells may  
include macrophages, DC, granulocytes.  
 




Second revision – authors’ response – 12 December 2014 
 
We have removed the cell type names (such as macrophages, B-cells) and refer to cell populations as 
CD11b+ cells or B220+ cells as suggested by the reviewer in supplementary figure legends and in the 
main text. 
  
Peer review correspondence 
Pertaining to the reviewer's following comment ( It should be noted that CpG (depending on the class) can 
also induce IFN-I in pDC via TLR9-MyD88-IRF7 pathway), we have modified one sentence in the 
discussion section to accommodate this information as follows: In contrast to A-class CpG ODN that 
induce type I IFN in pDC via TLR9-MyD88-IRF7 pathway, recognition of conventional CpG-ODN (Class B) 
by endosomal TLR9 initiates a signaling cascade where MyD88-dependent recruitment of IRAK-4/IRAK-
1/TRAF6 leads to the activation of TAK1 (transforming-growth-factor-beta-activated kinase). 
 With respect to the Editor's comments, we have accepted all suggested changes and included missing 
information about the replicates in the Figure legends. 
 We hope that our re-revised manuscript is satisfactory for publication in EJI.  
Once again we that the reviewer and the Editor for their valuable time, comments and suggestions. 
 
 
Third Editorial Decision – 19 December 2014 
 
Dear Dr. Gursel,  
 
It is a pleasure to provisionally accept your manuscript entitled "Enhanced immunostimulatory activity of 
cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with 
CpG" for publication in the European Journal of Immunology. For final acceptance, please follow the 
instructions below and return the requested items as soon as possible as we cannot process your 
manuscript further until all items listed below are dealt with. 
  
Please note that EJI articles are now published online a few days after final acceptance (see Accepted 
Articles: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141/accepted). The files used for the 
Accepted Articles are the final files and information supplied by you in Manuscript Central. You should 
therefore check that all the information (including author names) is correct as changes will NOT be 
permitted until the proofs stage. 
  
We look forward to hearing from you and thank you for submitting your manuscript to the European 
Journal of Immunology. 
  
Yours sincerely,  
Karen Chu  
 
on behalf of Prof. Marco Colonna  
 
Dr. Karen Chu  
Editorial Office  
Peer review correspondence 
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